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BRIEF COMMUNICATION
Botulinum Toxin-A Treatment
Reduces Human Mechanical
Pain Sensitivity and
Mechanotransduction
Kathryn Paterson, MRes,1
Stephane Lolignier, PhD,2
John N. Wood, FRS,2
Stephen B. McMahon, FMedSci,1 and
David L. H. Bennett, FRCP3
The mechanisms underlying the analgesic effects of
botulinum toxin serotype A (BoNT-A) are not well
understood. We have tested the hypothesis that
BoNT-A can block nociceptor transduction. Intradermal
administration of BoNT-A to healthy volunteers pro-
duced a marked and specific decrease in noxious
mechanical pain sensitivity, whereas sensitivity to low-
threshold mechanical and thermal stimuli was
unchanged. BoNT-A did not affect cutaneous innerva-
tion. In cultured rodent primary sensory neurons,
BoNT-A decreased the proportion of neurons express-
ing slowly adapting mechanically gated currents linked
to mechanical pain transduction. Inhibition of mecha-
notransduction provides a novel locus of action of
BoNT-A, further understanding of which may extend
its use as an analgesic agent.
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Botulinum toxin serotype A (BoNT-A) is widely usedin the treatment of conditions of muscle or glandu-
lar hyperactivity.1 Inhibition of vesicular release of
acetylcholine is achieved by receptor-mediated entry of
BoNT-A into presynaptic nerve terminals followed by
cleavage of the 25kDa synaptosomal-associated protein
(SNAP-25) required for presynaptic vesicular docking.
BoNT-A has recently been noted to have analgesic effects
in animal models of inflammatory and neuropathic
pain2,3 and clinically has efficacy in the treatment of
headache4 and neuropathic pain.5
The mechanisms by which the analgesic effects of
BoNT-A are mediated are not fully understood. One
mechanism is the inhibition of neurogenic inflammation
by blocking neurotransmitter release from sensitized
nociceptors, reducing peripheral sensitization.6 In vitro,
BoNT-A has been found to inhibit neuropeptide release,7
and BoNT-A reduces the vascular response to algogens
such as capsaicin applied to human skin.8 Other poten-
tial analgesic mechanisms include retrograde transport of
BoNT-A by sensory neurons and inhibition of neuro-
transmitter release by their central terminals.9 We have
tested the hypothesis that BoNT-A can have modality-
specific effects on sensory function through alterations in
nociceptor transduction.
Our ability to perceive specific sensory modalities is
critically dependent on the detection of the sensory stim-
uli by specialized populations of sensory neurons. The
past 2 decades have led to a much clearer understanding
of the molecular and biophysical processes underlying
sensory transduction.10 This is mediated by ion channels
and G-protein–coupled receptors expressed at neuron ter-
minals and activated by specific stimuli. The pattern in
which these molecules are expressed determines the
response of sensory neurons to particular thermal,
mechanical, and chemical stimuli. The neural substrates
underling different sensory modalities are distinct and as
such can be manipulated independently both in disease
states and by therapeutics.11 We first investigated whether
treatment of humans with BoNT-A resulted in altered
perception of specific sensory modalities and found that
intradermal administration of BoNT-A to healthy volun-
teers selectively reduced mechanical pain sensibility.
The molecular identity of the ion channel that
responds to noxious mechanical stimuli is not yet known;
however, it can be studied electrophysiologically by meas-
uring mechanically gated currents in rodent sensory neu-
rons in culture. Such currents have rapidly adapting (RA)
or slowly adapting (SA) kinetics underlying low-
threshold responses and mechanical nociception, respec-
tively.12 In the second part of this study, we examine the
effects of BoNT-A on this transduction machinery to
investigate the mechanism underlying the reduction in
mechanical pain perception.
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Subjects and Methods
Healthy volunteers were recruited to take part in this
study (12 male, 12 female; median age5 26 years,
range5 21-33 years). Each participant provided written
informed consent prior to commencing each experiment
in compliance with the declaration of Helsinki, and the
protocol was conducted in accordance with the King’s
College London (BDM 10/11-84) and National Health
Service research ethical committees (11-LO-0159). Sub-
jects underwent baseline quantitative sensory testing
(QST) to the lateral lower leg 9cm above the lateral mal-
leolus. Intradermal injections were given at 8 and 10cm
above the lateral malleolus. One leg received two 200ll
injections of 10U BoNT-A (Xeomin) in 0.9% saline, and
the other was injected with saline alone (the side that
received BoNT-A was randomized). Subsequent QST was
performed at weekly intervals for 4 weeks in a double-
blinded fashion.
QST
QST followed protocols of the German Research Network
on Neuropathic Pain,13 including measurement of warm
and cooling detection thresholds, cold and heat pain
thresholds, mechanical detection threshold, mechanical
pain threshold, and windup ratio (WUR; a measure of cen-
tral facilitation of sensory processing). Following BoNT-A
injection, 4 weekly QST sessions were performed. Hista-
mine iontophoresis (1% aqueous solution delivered using a
10-second 1mA current) and topical 50% allyl isothiocya-
nate (AITC) were given as chemical challenges in the final
week.14 Tracing onto acetate 10 minutes after histamine or
AITC was used to calculate flare area.
As a positive control, sudomotor function was
tested using Minor’s starch–iodine test15 to define the
anhydrous area. Finally, 3mm skin punch biopsies were
taken from vehicle and BoNT-A–treated sites (Fig 1A).
Skin was processed as previously described to determine
intraepidermal nerve fiber density (IENFD).16
Sensory Neuronal Cultures and
Electrophysiological Recordings
Dissociated cultures of thoracic and lumbar dorsal root
ganglions from 6- to 10-week-old C57Bl6/J mice and
assessment of mechanically gated currents were per-
formed as previously described.12 Ten units per milliliter
BoNT-A or the equivalent volume of saline was added to
each dish immediately after culture, and cells were used
for patch clamp studies 486 4 hours after BoNT-A
treatment. Small dorsal root ganglion neurons (<30pF)
were selected for electrophysiological recordings. KCl-
containing pipette solution was used for all recordings.
Mechanical stimulation of cell bodies was achieved using
a heat-polished glass pipette controlled by a piezoelectric
crystal drive (Burleigh LSS-3000; Thorlabs, Newton,
NJ). Two hundred fifty–millisecond mechanical stimula-
tion steps were applied every 10 seconds in 1lm incre-
ments. Cells were considered as nonresponding when no
current >10pA was observed in response to a 12lm
stimulus. Responding cells were classified according to
the adaptation kinetics of their currents (see Fig 3B).
FIGURE 1: Psychophysics methodology. (A) Study design
and sequence of psychophysical testing. AITC5allyl isothio-
cyanate; BoNT-A5botulinum toxin serotype A; CDT5 cold
detection threshold; CPT5 cold pain threshold; MDT5me-
chanical detection threshold; MPT5mechanical pain thresh-
old; QST5quantitative sensory testing; TSL5 thermal
sensory limen; WDT5warm detection threshold;
WUR5windup ratio. (B) Distal leg sites were tested bilater-
ally. Dotted area represents area of BoNT-A treatment as
revealed by the Minor sudomotor function test. This area
and the corresponding contralateral area were divided into
4 sites as shown.
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Data Analysis
All QST data were analyzed for each subject as a propor-
tion of their baseline. Weekly QST data were analyzed
using 2-way repeated measures analysis of variance
(ANOVA) with Bonferroni post hoc analysis. Current
clamp data (firing threshold and resting potential) were
analyzed using unpaired t test. Voltage clamp data were
analyzed using the chi-square test on raw cell numbers.
Results
A schematic illustration of the study design is shown in
Figure 1A. The starch–iodine test (Minor test) for sudo-
motor function confirmed adequate treatment with
BoNT-A in all cases (mean anhydrous area was
17.96 2.4cm2; see Fig 1B). No subjects reported any
side effects from the treatment of either leg. BoNT-A
treatment reduced histamine-evoked itch and AITC-
evoked pain, and these changes were associated in both
cases with reduced flare area (in both cases p< 0.05
BoNT-A–treated skin compared to saline). Sensory
thresholds were determined at baseline and for 4 consec-
utive weeks following injection of BoNT-A or saline.
There was no change in the ability of subjects to detect
innocuous tactile stimuli (mechanical detection thresh-
old) over the study period (Fig 2). Mechanical pain
thresholds, however, were significantly increased in the
BoNT-A–treated region compared to the vehicle control
area (p< 0.001, BoNT-A vs saline, 2-way repeated meas-
ures ANOVA). The WURs were unchanged between
treatment areas. This is a psychophysical measure of
hypersensitivity due to temporal summation within the
central nervous system, and although a lack of effect on
WUR cannot completely exclude a central effect of
BoNT-A, it led us to hypothesize that BoNT-A could
directly impair the transduction of mechanical stimuli at
the periphery. In contrast to mechanical pain, we found
that thermal detection and pain thresholds were not sig-
nificantly different when comparing BoNT-A–treated
and saline-treated skin (data not shown). Topical treat-
ment with certain agents such as capsaicin cause altered
sensory thresholds due to local sensory axon degenera-
tion.17 However, there was no difference in IENFD
(p5 0.7470, paired t test, BoNT-A vs saline) following
BoNT-A treatment, and morphologically the fibers
appeared normal. This suggests that the reduction in
mechanical pain sensitivity was due to a functional effect
of BoNT-A on mechanosensitive nociceptors. Because
BoNT-A selectively increased mechanical pain threshold
but did not alter thermal detection or pain thresholds,
we investigated the impact of BoNT-A on
mechanotransduction.
The effect of BoNT-A on neuronal excitability and
mechanotransduction was assessed at the cellular level in
cultured mouse dorsal root ganglion neurons exposed to
10U/ml BoTN-A for 2 days. BoNT-A treatment had no
effect on the overall neuronal excitability, characterized
by the firing threshold in response to current injection,
or on the membrane resting potential, as shown in
Figure 3. RA and intermediately adapting mechanically
activated inward currents were unchanged. However,
there was a significant decrease in the proportion of cells
FIGURE 2: Mechanical quantitative sensory testing. Bilateral
mechanical quantitative sensory testing was performed
weekly. (A) No change was observed for mechanical detec-
tion threshold (MDT). (B) A significant increase in mechanical
pain threshold (MPT) from week 2 was demonstrated in bot-
ulinum toxin serotype A (BoNT-A)-treated skin compared to
saline control (week 2, p50.0361; week 3, p50.0065;
week 4, p50.0261; paired t test). (C) Windup ratios
remained unchanged. All data are represented as mean-
6 standard error of the mean, n524. **p<0.05, ***p<0.01.
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expressing an SA mechanically gated current (11 of 46
saline, 6 of 55 BoNT-A, p5 0.0410, chi-square test) in
response to local pressure applied to the cell soma. Fur-
ther analysis showed that BoNT-A treatment reduced by
3.5 fold the proportion of neurons expressing an SA cur-
rent with slow activation kinetics (specifically, 9 of 46
saline, 3 of 55 BoNT-A, p5 0.0145, chi-square test).
BoNT-A had no effect on the activation threshold of
FIGURE 3: Excitability and mechanically activated currents in botulinum toxin serotype A (BoNT-A)-treated sensory neurons. (A)
Excitability of small sensory neurons (<30pF) cultured for 48 hours in the presence of 10U/ml BoNT-A or saline was assessed
by current clamp recordings. Representative firing recorded in neurons in response to the injection of a ramp current of 1nA
over 1 second is shown. Bar graphs showing average capacitance, firing thresholds, and resting potentials are presented as
mean6 standard error of the mean. No significant differences were found (unpaired t test, n546 saline, n555 BoNT-A). (B)
Mechanically gated currents were subsequently recorded in the same neurons in voltage clamp mode and distinguished by
their adaptation kinetics. A significant reduction in the proportion of neurons showing a slowly adapting current was observed
in the BoNT-A–treated group (*p50.0410, chi-square test). This decrease specifically affects a subpopulation of cells showing
a slowly adapting/slowly activating current ($p50.0145 vs p50.3992 for slowly adapting/fast activating currents, chi-square
test). Representative traces of mechanically gated current types are shown as a legend. (C) Activation threshold and maximum
intensity of mechanically activated currents in sensory neurons, taken together or considering the slowly adapting currents
only. The activation threshold is given by the first stimulation intensity producing a current >10pA. No significant differences
were found (unpaired t test, n546–55 for all currents, n511–6 for slowly adapting currents). (D, E) Current–displacement
curves recorded from all neurons (D) or neurons showing a slowly adapting/slowly activating current only (E). As currents of
different natures are pooled together in D, values were normalized by the maximum current intensity for each cell.
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mechanically gated currents, and only a slight decrease in
the peak current intensity could be seen within the popu-
lation of neurons showing slowly adapting currents.
These results are consistent with our psychophysical
observations, as the SA mechanically gated current found
in dorsal root ganglion neurons has been linked to nox-
ious mechanosensation.12
Discussion
This study was designed to investigate the modality-
specific effects of intradermal injection of BoNT-A on
human sensory function. The BoNT-A treatment regime
reduced itch and pain sensibility in response to challenge
with histamine and AITC, respectively. In both cases
neurogenic flare was reduced, consistently with the
hypothesis that BoNT-A reduces neurogenic inflamma-
tion and in agreement with previous studies.6–8 We also
found that BoNT-A selectively reduced the subject’s sen-
sitivity to noxious mechanical stimuli, but there was no
change in response to low-threshold mechanical stimuli
or to thermal stimuli. The lack of effect of BoNT-A on
baseline thermal sensitivity is in agreement with other
studies.18 The effects of BoNT-A on mechanosensation
in naive human skin over this long time course has not
previously been determined. One study found no effect
of intracutaneous BoNT-A on mechanical pain threshold;
however, the longest time point at which this was
assessed was at 48 hours postinjection. Our data would
suggest that this is not an optimum time window to
detect change, given that the maximal effect we observed
was at week 3 postinjection.19 The increased mechanical
pain threshold is likely to represent changes in cutaneous
nociceptive afferents; we were careful to inject the
BoNT-A into the dermis, and the mechanical probes
used to assess mechanical pain thresholds selectively acti-
vate these cutaneous afferents.20 BoNT-A injected into
muscle (for instance in the treatment of disorders of
motor hyperactivity) may exert its effects on muscle affer-
ents by distinct mechanisms. BoNT-A has been reported
to impair neurite outgrowth in sensory neurons,21 but
we did not observe any change in innervation density in
BoNT-A–treated skin. The WUR, which provides a psy-
chophysical correlate of temporal summation leading to
central sensitization, did not change following BoNT-A
treatment, and so we investigated whether BoNT-A could
alter peripheral mechanotransduction.
BoNT-A had no effect on sensory neuronal excit-
ability or on the proportion of neurons expressing tran-
sient mechanically gated currents, but significantly
decreased the proportion of neurons expressing an SA
mechanically gated current. Neurons expressing this SA
mechanically gated current are believed to be involved in
mechanonociception, as blockade of the channel respon-
sible for this current by the conotoxin NMB-1 increases
mechanical pain thresholds, without affecting light touch
or heat sensitivity.12 The channel(s) responsible for this
current have yet to be identified. The TRPA1 channel is
required for the generation of an SA current in a subset
of peptidergic dorsal root ganglion neurons,22 and this
correlates with functional changes in sensory terminals
that demonstrate reduced action potential firing in
response to noxious peripheral mechanical stimulation
following TRPA1 blockade.23 However, TRPA1 is not
sufficient for mechanotransduction, as it is unable to
generate mechanically gated currents when expressed
alone in a heterologous system.22,24
Owing to its delayed and chronic effects in humans,
and the finding that BoNT-A in vitro decreased the pro-
portion of mechanosensitive cells showing slow currents, a
direct pharmacological action on mechanosensitive chan-
nels of the toxin is unlikely. A more plausible possibility is
an effect of BoNT-A on the trafficking of mechanosensitive
channels. In sensory neuron cultures, it has been shown
that the upregulation of mechanically gated currents by
inflammatory mediators acting through protein kinase C
activation is suppressed by blocking vesicle trafficking with
tetanus toxin.25 As more advanced preparations of BoNT-
A are produced, such as chimeric molecules that bind to
nociceptors more effectively,26 and methods for transder-
mal delivery are improved,27 the applications of BoNT-A
as an analgesic may be extended. One potential implication
of our findings is that patients with mechanical hypersensi-
tivity (for instance following traumatic nerve injury or
stump pain following limb amputation) may be more
likely to respond to BoNT-A. Insight into the effects of
BoNT-A on mechanotransduction, coupled with the
molecular identification of the trafficked mechanotrans-
ducing apparatus, should aid in the optimization and
assessment of the analgesic actions of BoNT-A.
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